# LTL-247 datasheet

| | | | |
|---|---|---|---|
| **Origin** | Primary human ovarian cancer | **Histopathology** | High grade serous adenocarcinoma |
| **Year of establishment** | 2006 | **Doubling time** | 13 days (sub-renal) |
| **Local invasion** | No | **Metastasis** | No |

**Drug sensitivity** carboplatin 80 mg/kg + paclitaxol 24mg/kg (T/C = 4.6 %, response)

The LTL-247 was developed from a patient's primary ovarian cancer (high-grade (grade 3/3) serous papillary adenocarcinoma). Histopathologically, it closely resembles the patient's tumor (Figs 1, 2). When grafted under the renal capsules of SCID mice, the LTL-247 shows no local invasion into adjacent host kidney parenchyma. No metastasis was observed.




**Fig. 1. H&E stained LTL-247 tissue sections.**

The LTL-247 is a high grade serous adenocarcinoma composed of solid sheets of tumor cells with histopathological characteristics similar to those of original patient's cancer (Fig2. A) . (x400)




**Fig. 2. Patient's cancer tissue before grafting.**

The tumor cells form **(A)** small solid nests or **(B)** fine papillae. (x400)

## Genetic and epigenetic characteristics

BRCA2 germline mutant.
Tissue microarrays containing LTL-247 tissue are available for screening potential molecular targets.

## Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), and angiogenesis.

2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.

3. Study of mechanisms underlying tumor growth and progression.

## References

1. Lee et al., Gynecologic Oncology 2005; 96: 48-61

2. Press et al., Gynecologic Oncology 2008; 110: 256-270

**For more information, please contact us by email: LTL@bccrc.ca or phone: (604) 675 8013**